pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ACETAdicet Bio, Inc.

$ACET
Boston, MA, USupdated 21d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Preclinical: 1Phase 1: 1Phase 2: 1
1Preclinical1Phase 11Phase 2
Phase 2
dactolisib tosylate + everolimus
Respiratory Tract Infections
Phase 1
prulacabtagene leucel
B-Cell Non-Hodgkin Lymphoma
Preclinical
ADI-212
Metastatic Castration-Resistant Prostate Cancer (mCRPC)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • —Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cellsactive not recruitingn=50
  • phase1A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Diseaseenrolling by invitationn=180
  • phase1A Phase 1 Study of ADI-001 in Rheumatoid Arthritisrecruitingn=25
  • phase2A Phase 1/2 Trial of ADI-270 in ccRCCactive not recruitingn=60
  • phase1A Phase 1 Study of ADI-001 in B Cell Malignanciesterminatedn=34

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 8, 26SELLORBIMED ADVISORS LLC· 40,416 sh @ $6.52−$264K↗
  • Apr 8, 26SELLORBIMED ADVISORS LLC· 32,523 sh @ $6.29−$205K↗
  • Apr 7, 26SELLORBIMED ADVISORS LLC· 29,319 sh @ $6.53−$191K↗
  • Apr 7, 26SELLORBIMED ADVISORS LLC· 2,400 sh @ $6.38−$15K↗
routine RSU / option mechanics (5)
  • Mar 25, 26grantHealey Don · Chief Technology Officer43,361 sh
  • Mar 25, 26grantAftab Blake · Chief Scientific Officer72,555 sh
  • Mar 25, 26grantHarvey Brian Nicholas · Chief Financial Officer43,361 sh
  • Mar 25, 26grantSchor Chen · President & CEO468,555 sh
  • Mar 25, 26grantMaltzman Julia D. · Chief Medical Officer72,555 sh
🐶 Hiring Signal
No open roles indexed yet — view Adicet Bio, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$ACET
SEC CIK
0001720580
country
US
source
sec_tickers
top tags
Oncology2Immunology1Lupus1Pulmonology1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 3m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?